Piri Keşif Aracı

Kaynak 1: http://www.sciencedirect.com/science/article/pii/S1876034120304810 arayıcılığı görüntüle.
Kaynak 2: http://dx.doi.org/10.1016/j.jiph.2020.05.015 arayıcılığı görüntüle.

Cilt: 13
Sayı: 6
Sayfa: 833

Sınıflandırma :

Biyotıp %32

İlaç Direnci %58

Epidemiyoloji %29

Çevre %22

Su ve Sağlık %63

Çevresel Sağlık %33

2

COVID-19 and the Eye

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

Journal of Infection

Yayıncı:

Elsevier

Yazar(lar) :

Yueyang Zhong , Kai Wang , Yanan Zhu , Danni Lyu , Ke Yao

Yıl :

2020

COVID-19 and the Eye

Ek Bilgiler

DOI : 10.1016/j.jinf.2020.05.054

ISSN: 0163-4453
Sayı: 2
Cilt: 81
Sayfa: e122-e123

Sınıflandırma :

Biyotıp %61

Epidemiyoloji %35

İlaç Direnci %24

3

Molecular Aspects of COVID-19 Differential Pathogenesis

Dergi Makalesi

Kaynak 1:

Directory of Open Access Journals (DOAJ)

Kaynak 2:

MDPI

Dergi:

Pathogens

Yazar(lar) :

Hussin A. Rothan , Arpan Acharya , St Patrick Reid , Mukesh Kumar , Siddappa N. Byrareddy

Yıl :

2020

Molecular Aspects of COVID-19 Differential Pathogenesis In the absence of therapeutic interventions, and a possible vaccine candidate, the spread of COVID- 19 disease and associated fatalities are on the rise The epidemiological data indicate that age, sex, and cardio-metabolic disease have a significant impact on the spread and severity of COVID- 19. COVID-19

Yayıncı Web Siteleri

Piri Tam Metin Bulucu Özet Ek Bilgiler

In the absence of therapeutic interventions, and a possible vaccine candidate, the spread of COVID-19 disease and associated fatalities are on the rise. The high mutation frequency in the genomic material of these viruses supports their ability to adapt to new environments, resulting in an efficient alteration in tissue tropism and host range. Therefore, the coronavirus’ health threats could be relevant for the long-term. The epidemiological data indicate that age, sex, and cardio-metabolic disease have a significant impact on the spread and severity of COVID-19. In this review, we highlight recent updates on the pathogenesis of SARS-CoV-2 among men and women, including children. We also discuss the role of the cellular receptors and coreceptors used by the virus to enter host cells on differential infection among men, women, and cardio-metabolic patients.

Kaynak 1: https://doi.org/10.3390/pathogens9070538 arayıcılığı görüntüle.
Kaynak 2: http://dx.doi.org/10.3390/pathogens9070538 arayıcılığı görüntüle.

DOI : 10.3390/pathogens9070538

Anahtar Kelimeler : SARS-COV-2, COVID-19, differential pathogenesis, comorbidity, cardio-metabolic disease

ISSN: 2076-0817
Cilt: 9
Sayı: 538
Sayfa: 538

Sınıflandırma :

Biyotıp %99

Viroloji %41

İlaç Direnci %20

4

COVID-19 precautions and recommendations

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

American Journal of Orthodontics and Dentofacial Orthopedics

Yayıncı:

Elsevier

Yazar(lar) :

Prabhat Kumar Chaudhari , Jitendra Sharan , Kelly Kathering Achachao Almerco

Yıl :

2020

COVID-19 precautions and recommendations

Ek Bilgiler

DOI : 10.1016/j.ajodo.2020.06.015

ISSN: 0889-5406
Sayı: 3
Cilt: 158
Sayfa: 312

Sınıflandırma :

Biyotıp %97

İlaç Direnci %48

Epidemiyoloji %20

5

COVID-19 Therapeutic and Prevention

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

International Journal of Antimicrobial Agents

Yayıncı:

Elsevier

Yazar(lar) :

Didier Raoult , Po-Ren Hsueh , Stefania Stefani , Jean-Marc Rolain

Yıl :

2020

COVID-19 Therapeutic and Prevention

Ek Bilgiler

DOI : 10.1016/j.ijantimicag.2020.105937

ISSN: 0924-8579
Sayı: 4
Cilt: 55
Sayfa: 105937

Sınıflandırma :

Biyotıp %51

İlaç Direnci %98

6

Azithromycin for severe COVID-19

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

The Lancet

Yayıncı:

Elsevier

Yazar(lar) :

Catherine E Oldenburg , Thuy Doan

Yıl :

2020

Azithromycin for severe COVID-19

Ek Bilgiler

DOI : 10.1016/s0140-6736(20)31863-8

ISSN: 0140-6736
Sayı: 10256
Cilt: 396
Sayfa: 936-937

Sınıflandırma :

Tıp ve Halk Sağlığı %43

Pediatri %62

Pnömoloji ve Solunum Sistemi %21

Biyotıp %38

İlaç Direnci %81

7

Of chloroquine and COVID-19

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

Antiviral Research

Yayıncı:

Elsevier

Yazar(lar) :

Franck Touret , Xavier de Lamballerie

Yıl :

2020

Of chloroquine and COVID-19

Ek Bilgiler

DOI : 10.1016/j.antiviral.2020.104762

ISSN: 0166-3542
Cilt: 177
Sayfa: 104762

Sınıflandırma :

Biyotıp %64

İlaç Direnci %38

Tropik ilaç %27

8

Pathology and Therapeutics of COVID-19: A Review

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

International Journal of Medical Students

Yazar(lar) :

Haleema Anwar , Qudsia Umaira Khan

Yıl :

2020

Pathology and Therapeutics of COVID-19: A Review COVID- 19 pandemic has taken over the world. COVID- 19 cases were first reported in December 2019 in China; it affects the lungs causing mild to severe respiratory disease. The article will provide a good insight into the COVID- 19 infection.

Piri Tam Metin Bulucu Özet Ek Bilgiler

COVID-19 pandemic has taken over the world. Spreading form its epicenter in a seafood market in Wuhan to more than 200 countries, it has caused alarming situations. The viral infection is caused by an RNA virus called SARS-CoV-2. Its genome resembles the SARS-CoV-1 and MERS-CoV genome. COVID-19 cases were first reported in December 2019 in China; it affects the lungs causing mild to severe respiratory disease. No antiviral drug for the infection has been approved yet, but certain drugs are under consideration including Chloroquine, Hydroxychloroquine and Teicoplanin. The review article will first present the structure of the SARS-CoV-2 and compare it to SARS-CoV-1 and MERS-CoV. The article will then highlight its effect on different organs. Finally, it will highlight the therapeutics which are in consideration and which are being used. The article will provide a good insight into the COVID-19 infection.

DOI : 10.5195/ijms.2020.498

Anahtar Kelimeler : pandemic, phylogenetic analysis, differential diagnosis, incubation period, viral genome

ISSN: 2076-6327

Sınıflandırma :

Biyotıp %98

Viroloji %57

İlaç Direnci %23

9

Use of antiviral drugs to reduce COVID-19 transmission

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

The Lancet Global Health

Yazar(lar) :

Oriol Mitjà , Bonaventura Clotet

Yıl :

2020

Use of antiviral drugs to reduce COVID-19 transmission

Ek Bilgiler

ISSN: 2214-109X
Cilt: 8
Sayı: 5
Sayfa: e639 - e640

Sınıflandırma :

Biyotıp %65

İlaç Direnci %48

Tıp ve Halk Sağlığı %23

Bulaşıcı Hastalıklar %48

Hepatoloji %37

10

Standing out from the crowd in treating COVID-19

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Medicine in Drug Discovery

Yazar(lar) :

Kim D. Janda , Michael J. Iadarola

Yıl :

2020

Standing out from the crowd in treating COVID-19

Ek Bilgiler

ISSN: 2590-0986
Cilt: 6
Sayfa: 100034

Sınıflandırma :

Biyotıp %24

İlaç Direnci %28

Popüler Yaşam Bilimleri %27

Hayvan Modelleri %22

11

Extra-respiratory manifestations of COVID-19

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

International Journal of Antimicrobial Agents

Yayıncı:

Elsevier

Yazar(lar) :

Chih-Cheng Lai , Wen-Chien Ko , Ping-Ing Lee , Shio-Shin Jean , Po-Ren Hsueh

Yıl :

2020

Extra-respiratory manifestations of COVID-19

Ek Bilgiler

DOI : 10.1016/j.ijantimicag.2020.106024

ISSN: 0924-8579
Sayı: 2
Cilt: 56
Sayfa: 106024

Sınıflandırma :

Biyotıp %28

İlaç Direnci %86

Tıp ve Halk Sağlığı %27

Pediatri %37

12

Procalcitonin levels in COVID-19 patients

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

International Journal of Antimicrobial Agents

Yayıncı:

Elsevier

Yazar(lar) :

Rui Hu , Chaofei Han , Shiyao Pei , Mingzhu Yin , Xiang Chen

Yıl :

2020

Procalcitonin levels in COVID-19 patients

Ek Bilgiler

DOI : 10.1016/j.ijantimicag.2020.106051

ISSN: 0924-8579
Sayı: 2
Cilt: 56
Sayfa: 106051

Sınıflandırma :

Biyotıp %86

İlaç Direnci %83

13

Drug repurposing against COVID-19: focus on anticancer agents

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Journal of Experimental & Clinical Cancer Research

Yazar(lar) :

Gennaro Ciliberto , Rita Mancini , Marco G. Paggi

Yıl :

2020

Drug repurposing against COVID-19: focus on anticancer agents Abstract Background The very limited time allowed to face the COVID- 19 pandemic poses a pressing challenge to find proper therapeutic approaches. Most drugs considered for repurposing/repositioning in the therapy of the COVID- 19 outbreak are commercially available and their dosage and toxicity in Several drugs being re-considered for COVID- 19 therapy are or have been used in cancer therapy.

Piri Tam Metin Bulucu Özet Ek Bilgiler

Abstract Background The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. Main Body Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II–III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the “viral program”. Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. Short Conclusion To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19.

DOI : 10.1186/s13046-020-01590-2

Anahtar Kelimeler : Health emergencies, Viral pneumonia, Anticancer drugs, Drug repurposing, Immune response

ISSN: 1756-9966
Cilt: 39
Sayı: 1
Sayfa: 1 - 9

Sınıflandırma :

Biyotıp %99

İlaç Direnci %43

14

COVID-19: the current situation in Nepal

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

New Microbes and New Infections

Yayıncı:

Elsevier

Yazar(lar) :

B. Panthee , S. Dhungana , N. Panthee , A. Paudel , S. Gyawali , S. Panthee

Yıl :

2020

COVID-19: the current situation in Nepal

Ek Bilgiler

DOI : 10.1016/j.nmni.2020.100737

ISSN: 2052-2975
Cilt: 37
Sayfa: 100737

Sınıflandırma :

Biyotıp %34

Tropik ilaç %66

İlaç Direnci %27

Yaşam Bilimleri %29

Tarım %98

15

Emerging vaccine delivery systems for COVID-19

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

Drug Discovery Today

Yayıncı:

Elsevier

Yazar(lar) :

Nigel Theobald

Yıl :

2020

Emerging vaccine delivery systems for COVID-19

Ek Bilgiler

DOI : 10.1016/j.drudis.2020.06.020

ISSN: 1359-6446
Sayı: 9
Cilt: 25
Sayfa: 1556-1558

Sınıflandırma :

Biyotıp %72

İlaç Direnci %21

Tropik ilaç %20

16

Amphotericin B as antiviral drug: Possible efficacy against COVID-19

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Annals of Thoracic Medicine

Yazar(lar) :

Falah Hasan Obayes AL-Khikani

Yıl :

2020

Amphotericin B as antiviral drug: Possible efficacy against COVID-19 COVID- 19 is regarding the new genera of coronaviridae that appear the first time in Wuhan, China, in early December 2019. Due to the continuous spreading of the novel COVID- 19 with the exponential rise in death numbers, new therapeutic development is urgent, in general, there - 19. covid-19

Piri Tam Metin Bulucu Özet Ek Bilgiler

Since its discovery, amphotericin B (AmB) is still one of the most common first-line choices in treatment pulmonary mycoses for over seventh decades from discovery. AmB which is belonged to the polyene group has a wide spectrum in vitro and in vivo antimicrobial activity against fungi and parasites, resistance to AmB is rare despite extensive use. Recently, some studies focused on the potential antimicrobial action of AmB against some enveloped viruses such as human immunodeficiency virus, Japanese encephalitis virus, and rubella virus. Coronaviruses are enveloped positive-sense RNA nucleic acid viruses that have club-like spikes, characterized by a distinctive replication strategy; they are round and sometimes pleomorphic shapes. COVID-19 is regarding the new genera of coronaviridae that appear the first time in Wuhan, China, in early December 2019. Due to the continuous spreading of the novel COVID-19 with the exponential rise in death numbers, new therapeutic development is urgent, in general, there are no specific antiviral drugs or vaccines for 2019-novel coronavirus. Hence, this review may serve as an impetus for researchers working in the field of medical microbiology, vaccination, and antiviral drug design by discussion the most recent information about the antiviral action of AmB against COVID-19 infection as well as trying to a deep understanding of major properties, mechanisms of action, immune system responses, and antimicrobial efficiency of AmB. Since AmB is expected to alter the structure of the viral envelope, membrane integrity of cells, and internal cellular organelles, besides its other unique properties such as host immunomodulatory effects, so this review suggested that AmB as an effective anti-fungi drug thus may hold the promise of formulating a novel therapeutic option to treat COVID-19.

DOI : 10.4103/atm.ATM_147_20

Anahtar Kelimeler : amphotericin b, antimicrobial agents, antiviral drugs, coronavirus, covid-19

Cilt: 15
Sayı: 3
Sayfa: 118 - 124

Sınıflandırma :

Biyotıp %80

İlaç Direnci %100

17

Directly Acting Antivirals for COVID-19: Where Do We Stand?

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Frontiers in Microbiology

Yazar(lar) :

Siew L. Teoh , Yi H. Lim , Nai M. Lai , Nai M. Lai , Nai M. Lai , Shaun W. H. Lee , Shaun W. H. Lee , Shaun W. H. Lee

Yıl :

2020

Directly Acting Antivirals for COVID-19: Where Do We Stand? - 19). This rapid review aims to describe the directly acting antivirals that have been examined for use in the management of COVID- 19. - 19 to identify for case reports, case series, observational studies, and randomized controlled studies describing the use of antivirals in COVID- 19. COVID-19

Piri Tam Metin Bulucu Özet Ek Bilgiler

The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has now become a pandemic with no approved therapeutic agent. At the moment, the genomic structure, characteristics, and pathogenic mechanisms of SARS-CoV-2 have been reported. Based upon this information, several drugs including the directly acting antivirals have been proposed to treat people with coronavirus disease 2019 (COVID-19). This rapid review aims to describe the directly acting antivirals that have been examined for use in the management of COVID-19. Searches were conducted in three electronic databases, supplemented with a search on arXiv, bioRxiv, medRxiv, ChinaXiv, ClinicalTrials.gov, and Chinese Clinical Trial Registry for studies examining the use of antivirals in COVID-19 to identify for case reports, case series, observational studies, and randomized controlled studies describing the use of antivirals in COVID-19. Data were extracted independently and presented narratively. A total of 98 studies were included, comprising of 38 published studies and 60 registered clinical trials. These drugs include the broad spectrum antivirals such as umifenovir, protease inhibitors such as lopinavir/ritonavir as well as the RNA-dependent RNA polymerase inhibitors, remdesivir, and favipiravir. Other drugs that have been used include the nucleosidase inhibitors and polymerase acidic endonuclease inhibitors which are currently approved for prevention of influenza infections. While some of the drugs appear promising in small case series and reports, more clinical trials currently in progress are required to provide higher quality evidence.

DOI : 10.3389/fmicb.2020.01857

Anahtar Kelimeler : rapid review, systematic review, COVID-19, antivirals, pandemic

ISSN: 1664-302X
Cilt: 11

Sınıflandırma :

Biyotıp %58

Viroloji %74

İlaç Direnci %22

Tıp ve Halk Sağlığı %41

Bulaşıcı Hastalıklar %72

18

PAK1-blockers: Potential Therapeutics against COVID-19

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

Medicine in Drug Discovery

Yayıncı:

Elsevier

Yazar(lar) :

Hiroshi Maruta , Hong He

Yıl :

2020

PAK1-blockers: Potential Therapeutics against COVID-19

Ek Bilgiler

DOI : 10.1016/j.medidd.2020.100039

ISSN: 2590-0986
Cilt: 6
Sayfa: 100039

Sınıflandırma :

Biyotıp %92

İlaç Direnci %58

19

Current Status of COVID-19 Therapies and Drug Repositioning Applications

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

iScience

Yazar(lar) :

Ozlem Altay , Elyas Mohammadi , Simon Lam , Hasan Turkez , Jan Boren , Jens Nielsen , Mathias Uhlen , Adil Mardinoglu

Yıl :

2020

Current Status of COVID-19 Therapies and Drug Repositioning Applications rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID - 19. Here, we review current information concerning the global health issue of COVID- 19 including promising approved drugs and ongoing clinical trials for prospective

Özet Ek Bilgiler

The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. Here, we review current information concerning the global health issue of COVID-19 including promising approved drugs and ongoing clinical trials for prospective treatment options. In addition, we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against SARS-CoV-2.

Anahtar Kelimeler : Health Sciences, Medicine

ISSN: 2589-0042
Cilt: 23
Sayı: 7
Sayfa: 101303

Sınıflandırma :

Biyotıp %93

İlaç Direnci %48

Translasyon Sonrası Değişiklik %39

20

Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Frontiers in Artificial Intelligence

Yazar(lar) :

Arash Keshavarzi Arshadi , Julia Webb , Milad Salem , Emmanuel Cruz , Stacie Calad-Thomson , Niloofar Ghadirian , Jennifer Collins , Elena Diez-Cecilia , Brendan Kelly , Hani Goodarzi , Jiann Shiun Yuan

Yıl :

2020

Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development Understanding the pathobiology of COVID- 19 could aid scientists in their discovery of potent antivirals by elucidating unexplored viral pathways. In this review, we focus on the recent advances of COVID- 19 drug and vaccine development using artificial intelligence and the potential of intelligent training for the discovery of COVID- 19 therapeutics. COVID-19

Piri Tam Metin Bulucu Özet Ek Bilgiler

SARS-COV-2 has roused the scientific community with a call to action to combat the growing pandemic. At the time of this writing, there are as yet no novel antiviral agents or approved vaccines available for deployment as a frontline defense. Understanding the pathobiology of COVID-19 could aid scientists in their discovery of potent antivirals by elucidating unexplored viral pathways. One method for accomplishing this is the leveraging of computational methods to discover new candidate drugs and vaccines in silico. In the last decade, machine learning-based models, trained on specific biomolecules, have offered inexpensive and rapid implementation methods for the discovery of effective viral therapies. Given a target biomolecule, these models are capable of predicting inhibitor candidates in a structural-based manner. If enough data are presented to a model, it can aid the search for a drug or vaccine candidate by identifying patterns within the data. In this review, we focus on the recent advances of COVID-19 drug and vaccine development using artificial intelligence and the potential of intelligent training for the discovery of COVID-19 therapeutics. To facilitate applications of deep learning for SARS-COV-2, we highlight multiple molecular targets of COVID-19, inhibition of which may increase patient survival. Moreover, we present CoronaDB-AI, a dataset of compounds, peptides, and epitopes discovered either in silico or in vitro that can be potentially used for training models in order to extract COVID-19 treatment. The information and datasets provided in this review can be used to train deep learning-based models and accelerate the discovery of effective viral therapies.

DOI : 10.3389/frai.2020.00065

Anahtar Kelimeler : COVID-19, SARS-COV-2, vaccine, artificial intelligence, deep learning

ISSN: 2624-8212
Cilt: 3

Sınıflandırma :

Biyotıp %99

İlaç Direnci %22

21

Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Frontiers in Pharmacology

Yazar(lar) :

Piero Sestili , Vilberto Stocchi

Yıl :

2020

Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19 The COVID- 19 pandemic is posing an unprecedented sanitary threat. The repositioning of available drugs to treat COVID- 19 is the only and rapid option in the face of the lack of direct antiviral agents and vaccines available - 19’s worst complications. COVID-19

Piri Tam Metin Bulucu Özet Ek Bilgiler

The COVID-19 pandemic is posing an unprecedented sanitary threat. In the absence of specific vaccines and anti-SARS-CoV-2 drugs, medicines that may assist in tackling the emergency and limiting the high number of fatalities are urgently needed. The repositioning of available drugs to treat COVID-19 is the only and rapid option in the face of the lack of direct antiviral agents and vaccines available. In this light it is important to focus on available drugs, which, based on their pharmacodynamics, could plausibly attenuate viral growth as well as COVID-19’s worst complications. This is the case of chloroquine and tocilizumab which seem to limit virus replication and the severity of interstitial pneumonia, respectively. However, these treatments, particularly those aimed at containing inflammation, are still reserved for the most severe cases. This commentary elaborates on the pharmacological rationale of repositioning the mast cell stabilizer chromones as an adjunctive treatment for SARS‐CoV‐2 infection, and proposes their practical clinical testing as an early, safe, and cost-effective anti-inflammatory intervention in COVID-19 to limit the eventual secondary progression toward life-threatening respiratory complications.

DOI : 10.3389/fphar.2020.00854

Anahtar Kelimeler : COVID-19, inflammation, lung injury, chromones, mast cells

ISSN: 1663-9812
Cilt: 11

Sınıflandırma :

Biyotıp %65

Viroloji %34

İlaç Direnci %23

Tıp ve Halk Sağlığı %35

Farmakoterapi %76

22

Regulators split on antimalarials for COVID-19

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

The Lancet

Yayıncı:

Elsevier

Yazar(lar) :

Susan Jaffe

Yıl :

2020

Regulators split on antimalarials for COVID-19

Ek Bilgiler

DOI : 10.1016/s0140-6736(20)30817-5

ISSN: 0140-6736
Sayı: 10231
Cilt: 395
Sayfa: 1179

Sınıflandırma :

Biyotıp %37

Tropik ilaç %78

İlaç Direnci %22

Hukuk %30

Afrika Ekonomisi %67

Tıp Hukuku %33

Tıp ve Halk Sağlığı %30

Kulak Burun Boğaz Hastalıkları %96

23

COVID-19: don't neglect antimicrobial stewardship principles!

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

Clinical Microbiology and Infection

Yayıncı:

Elsevier

Yazar(lar) :

B.D. Huttner , G. Catho , J.R. Pano-Pardo , C. Pulcini , J. Schouten

Yıl :

2020

COVID-19: don't neglect antimicrobial stewardship principles!

Ek Bilgiler

DOI : 10.1016/j.cmi.2020.04.024

ISSN: 1198-743X
Sayı: 7
Cilt: 26
Sayfa: 808-810

Sınıflandırma :

Biyotıp %77

İlaç Direnci %100

24

COVID-19 and cancer care in Bermuda

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

The Lancet Oncology

Yayıncı:

Elsevier

Yazar(lar) :

Christopher Fosker

Yıl :

2020

COVID-19 and cancer care in Bermuda

Ek Bilgiler

DOI : 10.1016/s1470-2045(20)30272-2

ISSN: 1470-2045
Sayı: 6
Cilt: 21
Sayfa: 761-762

Sınıflandırma :

Tıp ve Halk Sağlığı %76

Cerrahi Onkoloji %46

Biyotıp %23

İlaç Direnci %100

25

Combating devastating COVID-19 by drug repurposing

Dergi Makalesi

Kaynak :

Science Direct

Dergi:

International Journal of Antimicrobial Agents

Yayıncı:

Elsevier

Yazar(lar) :

Ashish Yashwantrao Pawar

Yıl :

2020

Combating devastating COVID-19 by drug repurposing

Ek Bilgiler

DOI : 10.1016/j.ijantimicag.2020.105984

ISSN: 0924-8579
Sayı: 2
Cilt: 56
Sayfa: 105984

Sınıflandırma :

Biyotıp %88

İlaç Direnci %98

26

Progress in the Research and Development of Anti-COVID-19 Drugs

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Frontiers in Public Health

Yazar(lar) :

Lianzhou Huang , Yuanqiu Chen , Ji Xiao , Weisheng Luo , Feng Li , Yuan Wang , Yiliang Wang , Yifei Wang

Yıl :

2020

Progress in the Research and Development of Anti-COVID-19 Drugs COVID- 19 spread rapidly around the world in a short time. of specific drugs for the treatment of COVID- 19. We also discussed the strategies of the development of anti- COVID- 19 drugs in the future. COVID-19 anti-COVID-19 drugs

Piri Tam Metin Bulucu Özet Ek Bilgiler